Drug intelligence / Profile preview

Lutetium (177Lu) DGUL

Development stage: Phase 2
Lead developer: Cellbion
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**Lutetium (177Lu) DGUL** is an investigational radiopharmaceutical consisting of lutetium-177 (a beta-emitting radioisotope) conjugated to a PSMA-targeting ligand (DGUL), designed for targeted radionuclide therapy in prostate cancer. It selectively binds to prostate-specific membrane antigen (PSMA) on tumor cells, delivering radiation to induce DNA damage and cell death in PSMA-expressing lesions while minimizing exposure to healthy tissues. Developed by Cellbion Co., Ltd., it is primarily indicated for metastatic castration-resistant prostate cancer (mCRPC) and is being evaluated in combination with pembrolizumab in early-phase trials assessing safety, dosimetry, and efficacy endpoints like radiographic progression-free survival.[3][13][15]

Other names: 177Lu-DGUL

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on Lutetium (177Lu) DGUL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lutetium (177Lu) DGUL.

Explore the full profile